Acute hyperglycemia and reperfusion therapy in stroke patients

Česká verzia

Authors: D. Krajíčková
Authors place of work: Neurologická klinika Lékařské fakulty UK a FN Hradec Králové, přednosta MU Dr. Radomír Taláb, CSc.
Published in the journal: Vnitř Lék 2010; 56(4): 295-300
Category: 11th National Diabetes Symposium "Diabetes and Angiology", Hradec Kralove, 5 to 6 June 2009

Summary

Current acute therapies for ischemic stroke are limited. Only a small proportion of stroke patients are eligible to receive reperfusion therapy. Acute hyperglycemia has a deleterious effect in stroke patients by accelerating ischemic brain damage. The complex relationship between hyperglycemia and stroke is discussed. In tPA‑treated patients, the acute but not chronic hyperglycemic state may hamper fibrinolytic process, delaying reperfusion of ischemic penumbra. Early measures to reduce hyperglycemia may favor early recanalization.

Key words:
hyperglycemia – reperfusion therapy – acute ischemic stroke

Zdroje

1. Kiers L, Davis SM, Larkins R et al. Stroke topography and outcome in relation to hyperglycaemia and diabetes. J Neurol Neurosurg Psychiatry 1992; 55: 263– 270.

2. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta‑analysis. Stroke 2007; 38: 967– 973.

3. Lojík M, Krajíčková D, Krajina A et al. Endovaskulární léčba u akutní mozkové ischemie – trombolýza a mechanická embolektomie. Čes Ger Rev 2009; 7: 63– 67.

4. The NINDS t‑ PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581– 1587.

5. Brott T, Adams HP Jr, Olinger CP et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20: 864– 870.

6. Krajíčková D, Krajina A. Cévní mozkové příhody u diabetiků – klinické projevy a léčba. Vnitř Lék 2005; 51 (Suppl 2): S12– S19.

7. De Keyser J, Gdovinová Z, Uyttenboogaart M et al. Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations. Stroke 2007; 38: 2612– 2618.

8. Hacke W, Kaste M, Bluhmski E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317– 1329.

9. Lee KL, Han SW, Kim SH et al. Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre‑ and post‑thrombolytic angiography in acute ischemic stroke patients. Stroke 2007; 38: 192– 193.

10. IMS Study Investigators. Combined intravenous and intra‑ arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004; 35: 904– 911.

11. Smith WS, Sung G, Starkman S et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005; 36: 1432– 1438.

12. Smith WS, Sung G, Saver J et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 2008; 39: 1205– 1212.

13. Nogueira RG, Smith WS. MERCI and Multi MERCI Writing Committee. Safety and efficacy of endovascular thrombectomy in patients with abnormal hemostasis. Pooled analysis of the MERCI and Multi MERCI trials. Stroke 2009; 40: 516– 522.

14. Wardlaw JM, Sandercock PAG, Berge E.Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta‑analysis. Stroke 2003; 34: 1437– 1442.

15. Hacke W, Albers G, Al‑ Rawi Y et al. The desmoteplase in acute ischaemic stroke trial: a phase II MRI‑based 9- hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 63– 73.

16. Katzan IL, Hammer MD, Furlan AJ et al. Cleveland Clinic Health System Stroke Quality Improvement Team. Quality improvement and tissue‑type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke 2003; 34: 799– 800.

17. Katzan IL, Furlan AJ, Lloyd LE et al. Use of tissue‑type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283: 1151– 1158.

18. Wahlgren N, Ahmed N, Eriksson N et al. SITS‑ MOST Investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomised controlled trials. Safe Implementation of Thrombolysis in Stroke‑ MOnitoring STudy (SITS‑ MOST). Stroke 2008; 39: 3316– 3322.

19. Bateman BT, Schumacher HC, Boden‑ Albala B et al. Factors associated with in‑hospital mortality after administration of thrombolysis in acute ischemic stroke patients. An analysis of the Nationwide Inpatient Sample 1999 to 2002. Stroke 2006; 37: 440– 446.

20. Gray CS, Tailor R, French JM et al. The prognostic value of stress hyperglycaemia and previously unrecognized diabetes in acute stroke. Diabet Med 1987; 4: 237– 240.

21. Sprafka JM, Virnig BA, Shahar E et al. Trends in diabetes prevalence among stroke patients and the effect of diabetes on stroke survival: the Minnesota Heart Survay. Diabet Med 1994; 11: 678– 684.

22. Melamed E. Reactive hyperglycaemia in patients with acute stroke. J Neurol Sci 1976; 29: 267– 275.

23. Weir CJ, Murray GD, Dyker AG et al. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study. BMJ 1997; 314: 1303– 1306.

24. Williams LS, Rotich J, Fineberg N et al. Effects of admission hyperglycemia on mortality and outcome in acute ischemic stroke. Neurology 2002; 59: 67– 71.

25. Capes SE, Hunt D, Malmberg K et al. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001; 32: 2426– 2432.

26. Garg R, Chaudhuri A, Munschauer F et al. Hyperglycemia, insulin, and acute ischemic stroke. A mechanistic justification for a trial of insulin infusion therapy. Stroke 2006; 37: 267– 273.

27. McCormick MT, Muir KW, Gray CS et al. Management of hyperglycemia in acute stroke. How, when, and for whom? Stroke 2008; 39: 2177– 2185.

28. Murros K, Fogelholm R, Kettunen S et al. Blood glucose, glycosylated hemoglobin, and outcome of ischemic brain infarction. J Neurol Sci 1992; 111: 59– 64.

29. Kawai N, Keep RF, Betz AL et al. Hyperglycemia induces progressive changes in the cerebral microvasculature and blood‑ brain barrier transport during focal cerebral ischemia. Acta Neurochir Suppl 1998; 71: 219– 221.

30. Anderson RE, Tan WK, Martin HS et al. Effects of glucose and pao2 modulation on cortical intracellular acidosis, NADH redox state, and infarction in the ischemic penumbra. Stroke 1999; 30: 160– 170.

31. Li PA, Shuaib A, Miyashita H et al. Hyperglycemia enhances extracellular glutamate accumulation in rats subjected to forebrain ischemia. Stroke 2000; 31: 183– 192.

32. Berger L, Hakim AM. The association of hyperglycemia with cerebral edema in stroke. Stroke 1986; 17: 865– 871.

33. Marks JB, Raskin P. Cardiovascular risk in diabetes: a brief review. J Diabetes Complications 2000; 14: 108– 115.

34. Nordt TK, Klassen KJ, Schneider DJ et al. Augmentation of synthesis of plasminogen activator inhibitor type‑ 1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Tromb 1993; 13: 1822– 1828.

35. Pandolfi A, Ciaccari A, Cilli C et al. Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic aktivity and increase plasminogen activator inhibitor type 1 in the rat. Acta Diabetol 2001; 38: 71– 76.

36. Bruno A, Levine SR, Frankel MR et al. NINDS rt‑ PA Stroke Study Group. Admission glucose level and clinical outcomes in the NINDS rt‑ PA trial. Neurology 2002; 59: 669– 674.

37. Yong M, Kaste M. Dynamic hyperglycemia as a predictor of stroke outcome in the ECASS‑ II trial. Stroke 2008; 39: 2749– 2755.

38. Alvarez‑ Sabín A, Molina CA, Montaner J et al. Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator‑treated patients. Stroke 2003; 34: 1235– 1241.

39. Parsons MW, Barber PA, Desmond PM et al. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol 2002; 52: 20– 28.

40. Ribo M, Molina C, Montaner J et al. Acute hyperglycemia state is associated with lower tPA‑induced recanalization rates in stroke patients. Stroke 2005; 36: 1705– 1709.

41. Olsen TS, Langhorne P, Diener HC et al. European Stroke Initiative Executive Committee and Writting Committee. European Stroke Initiative recommendations for stroke management. Update 2003. Cerebrovasc Dis 2003; 16: 311– 337.

42. Adams HP, Adams RJ, Brott T et al. Guidelines for the early management of patients with ischemic stroke. A scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003; 34: 1056– 1083.

43. Adams HP Jr, del Zoppo G, Alberts MJet al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38: 1655– 1711.

44. Gray CS, Hildreth AJ, Alberti GK et al. GIST Collaboration. Poststroke hyperglycemia: natural history and immediate management. Stroke 2004; 35: 122– 126.

45. Scott JF, Robinson GM, French JM et al. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia. The Glucose Insulin in Stroke Trial (GIST). Stroke 1999; 30: 793– 799.

46. Walters MR, Weir CJ, Lees KR. A randomised controlled pilot study to investigate the potential benefit of intervention with insulin in hyperglycaemic acute ischaemic stroke patients. Cerebrovasc Dis 2006; 22: 116– 122.

47. Bruno A, Kent TA, Coull BM et al. Treatment of hyperglycemia in ischemic stroke (THIS). A randomized pilot trial. Stroke 2008; 39: 384– 389.